Ovid Therapeutics is creating impactful medicines for patients with neurological diseases. Today, nearly 50 million people live with epilepsies and the current treatment options available are ineffective. Ovid’s strategy is to create therapies that ameliorate neuronal hyperexcitability that arise with conditions like seizures and epilepsies. Their pipeline consists of small molecule programs that pursue unique targets implicated in neuronal regulation. While other companies focus on novel modalities, Ovid is taking advantage of the versatility of small molecules for manufacturing, chemistry and dosing. Ovid’s pipeline includes diverse indications in preclinical or clinical stages.

Ovid Therapeutics

Founded: 2014
Location: New York, NY
Employee range: 51-100
Funding: 100-500M

Short description:

Drug notes:

Long description:

Jobs: